Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis B reactivation during ruxolitinib treatment

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sant’Antonio E, Bonifacio M, Breccia M, Rumi E (2019) A journey through infectious risk associated with ruxolitinib. Br J Haematol 187(3):286–95

    Article  Google Scholar 

  2. Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian J-J, Cervantes F et al (2017) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 10(1):156

    Article  Google Scholar 

  3. Blum S, Martins F, Alberio L (2016) Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. J Blood Med 7:205–215

    Article  CAS  Google Scholar 

  4. Costanza M, Spertini O, Blum S (2020) Risk of B-cell lymphoma in MPN patients treated with JAK1/2 inhibitors: contradictory results? Leuk Res 90:106313

    Article  CAS  Google Scholar 

  5. Dioverti MV, Abu Saleh OM, Tande AJ (2018) Infectious complications in patients on treatment with ruxolitinib: case report and review of the literature. Infect Dis (Lond) 50(5):381–387

    Article  CAS  Google Scholar 

  6. Wathes R, Moule S, Milojkovic D (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 369(2):197–198

    Article  CAS  Google Scholar 

  7. Lussana F, Cattaneo M, Rambaldi A, Squizzato A (2018) Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol 93(3):339–347

    Article  CAS  Google Scholar 

  8. Prem S, Loach D, Lipton J, Kumar R, Gupta V (2019) EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis. Blood Res 54(4):282–284

    Article  Google Scholar 

  9. Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H et al (2011) Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 17(34):3881–3887

    Article  CAS  Google Scholar 

  10. Heine A, Held SAE, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C et al (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122(7):1192–1202

    Article  CAS  Google Scholar 

  11. McLornan DP, Khan AA, Harrison CN (2015) Immunological consequences of JAK inhibition: friend or foe? Curr Hematol Malig Rep 10(4):370–379

    Article  Google Scholar 

  12. Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G (2014) Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28(1):225–227

    Article  CAS  Google Scholar 

  13. Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A et al (2019) Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology A position paper by the European Conference on Infections in Leukemia ECIL Leukemia 33(4):844–62

    CAS  Google Scholar 

  14. Gill H, Leung GMK, Seto W-K, Kwong Y-L (2019) Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment. Ann Hematol 98(1):215–218

    Article  CAS  Google Scholar 

  15. Garcia-Horton A, Smith E, Maze D, McNamara C, Sibai H, Gupta V (2021) Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib. Leuk Lymphoma 62(2):495–497

    Article  CAS  Google Scholar 

  16. Duan M-H, Cao X-X, Chang L, Zhou D-B (2021) Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms. Hematology 26(1):460–464

    Article  CAS  Google Scholar 

  17. Kirito K, Sakamoto M, Enomoto N (2016) Elevation of the hepatitis B Virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med 55(10):1341–1344

    Article  CAS  Google Scholar 

  18. Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM (2017) A life-threatening ruxolitinib discontinuation syndrome. Am J Hematol 92(8):833–838

    Article  Google Scholar 

  19. Shen C-H, Hwang C-E, Chen Y-Y, Chen C-C (2014) Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 93(6):1075–1076

    Article  Google Scholar 

  20. Perricone G, Vinci M, Pungolino E (2017) Occult hepatitis B infection reactivation after ruxolitinib therapy. Dig Liver Dis 49(6):719

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emergency Service, Lausanne University Hospital (CHUV), Lausanne, Switzerland

    Marissa Sjoblom

  2. Service of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland

    Haithem Chtioui

  3. Division of Gastroenterology and Hepatology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland

    Montserrat Fraga

  4. Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Rue du Bugnon 46, CH-1011, Lausanne, Switzerland

    Gregoire Stalder, Francesco Grandoni & Sabine Blum

Authors
  1. Marissa Sjoblom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haithem Chtioui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Montserrat Fraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregoire Stalder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Grandoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sabine Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M. Sjoblom and H. Chtioui performed a review of literature. M. Sjoblom wrote the paper: M. Sjoblom and S. Blum wrote the paper. G Stalder treated the patient. M. Fraga Christinet revised the paper critically and contributed the specifics of HBV reactivation. S. Blum and F. Grandoni revised the paper critically. S. Blum oversaw the paper and is the corresponding author.

Corresponding author

Correspondence to Sabine Blum.

Ethics declarations

Informed consent

The patient gave informed consent to publication.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sjoblom, M., Chtioui, H., Fraga, M. et al. Hepatitis B reactivation during ruxolitinib treatment. Ann Hematol 101, 2081–2086 (2022). https://doi.org/10.1007/s00277-022-04851-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-04851-6

Search

Navigation